NasdaqCM:LPCN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men’s and women’s health.


Snowflake Analysis

High growth potential with adequate balance sheet.

Share Price & News

How has Lipocine's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LPCN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-7.4%

LPCN

-0.7%

US Pharmaceuticals

-0.7%

US Market


1 Year Return

-30.9%

LPCN

5.6%

US Pharmaceuticals

5.3%

US Market

Return vs Industry: LPCN underperformed the US Pharmaceuticals industry which returned 4.8% over the past year.

Return vs Market: LPCN underperformed the US Market which returned 6.7% over the past year.


Shareholder returns

LPCNIndustryMarket
7 Day-7.4%-0.7%-0.7%
30 Day42.0%3.8%4.6%
90 Day159.0%0.3%14.0%
1 Year-30.9%-30.9%8.4%5.6%7.6%5.3%
3 Year-72.5%-72.5%24.5%15.4%34.9%26.1%
5 Year-89.4%-89.4%25.6%11.2%62.3%44.7%

Price Volatility Vs. Market

How volatile is Lipocine's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Lipocine undervalued compared to its fair value and its price relative to the market?

9.13x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LPCN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate LPCN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: LPCN is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: LPCN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LPCN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LPCN is overvalued based on its PB Ratio (9.1x) compared to the US Pharmaceuticals industry average (3.3x).


Next Steps

Future Growth

How is Lipocine forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

38.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LPCN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: LPCN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: LPCN's is expected to become profitable in the next 3 years.

Revenue vs Market: LPCN's revenue (32% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: LPCN's revenue (32% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LPCN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Lipocine performed over the past 5 years?

8.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LPCN is currently unprofitable.

Growing Profit Margin: LPCN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LPCN is unprofitable, but has reduced losses over the past 5 years at a rate of 8.4% per year.

Accelerating Growth: Unable to compare LPCN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LPCN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.1%).


Return on Equity

High ROE: LPCN has a negative Return on Equity (-237.36%), as it is currently unprofitable.


Next Steps

Financial Health

How is Lipocine's financial position?


Financial Position Analysis

Short Term Liabilities: LPCN's short term assets ($21.0M) exceed its short term liabilities ($4.1M).

Long Term Liabilities: LPCN's short term assets ($21.0M) exceed its long term liabilities ($10.4M).


Debt to Equity History and Analysis

Debt Level: LPCN's debt to equity ratio (97%) is considered high.

Reducing Debt: Insufficient data to determine if LPCN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LPCN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LPCN has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 5.6% each year.


Next Steps

Dividend

What is Lipocine current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LPCN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LPCN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LPCN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LPCN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LPCN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average management tenure


CEO

Mahesh Patel (63yo)

23.5yrs

Tenure

US$520,553

Compensation

Dr. Mahesh V. Patel, Ph.D. co-founded Lipocine Inc. in 1997 and has also been its President and Chief Executive Officer since 1997. Dr. Patel has more than fifteen years of technology and product developme ...


CEO Compensation Analysis

Compensation vs Market: Mahesh's total compensation ($USD520.55K) is about average for companies of similar size in the US market ($USD612.38K).

Compensation vs Earnings: Mahesh's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Mahesh Patel
Co-Founder23.5yrsUS$520.55k2.03% $1.2m
Morgan Brown
Executive VP6.83yrsUS$377.46k0.13% $79.8k
Logan Morse
Vice President of Sales3.25yrsUS$633.01kno data
William Higuchi
Chief Scientific Consultantno dataUS$417.31kno data
Anthony DelConte
Chief Medical Director2.67yrsno datano data

5.0yrs

Average Tenure

62yo

Average Age

Experienced Management: LPCN's management team is seasoned and experienced (5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mahesh Patel
Co-Founder23.5yrsUS$520.55k2.03% $1.2m
Stephen Hill
Lead Independent Directorno dataUS$85.99k0.011% $6.6k
Leslie Benet
Member of Scientific Advisory Boardno datano datano data
Ronald Borchardt
Member of Scientific Advisory Boardno datano datano data
Jeffrey Fink
Independent Director6.5yrsUS$62.49k0.0020% $1.2k
George Zografi
Member of Scientific Advisory Boardno datano datano data
Tsuneji Nagai
Member of Scientific Advisory Boardno datano datano data
Alan Hofmann
Member of Scientific Advisory Boardno datano datano data
Norman Ho
Member of Scientific Advisory Boardno datano datano data
Rex Hjelm
Member of Scientific Advisory Boardno datano datano data
John Higuchi
Director17.5yrsUS$45.99k1.45% $870.6k
Bradley Anderson
Member of Scientific Advisory Boardno datano datano data

6.5yrs

Average Tenure

62yo

Average Age

Experienced Board: LPCN's board of directors are considered experienced (6.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 121.9%.


Top Shareholders

Company Information

Lipocine Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Lipocine Inc.
  • Ticker: LPCN
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$59.849m
  • Shares outstanding: 47.88m
  • Website: https://www.lipocine.com

Number of Employees


Location

  • Lipocine Inc.
  • 675 Arapeen Drive
  • Suite 202
  • Salt Lake City
  • Utah
  • 84108
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LPCNNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJul 2013
2VTDB (Deutsche Boerse AG)YesCommon StockDEEURJul 2013

Biography

Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company’s pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase II testing; LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase I Clinical trial for the treatment of non-alcoholic steatohepatitis. Lipocine Inc. is headquartered in Salt Lake City, Utah. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/14 00:06
End of Day Share Price2020/07/13 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.